- Home
- MVSTW vs RLAY Comparison
MVSTW vs RLAY Comparison
Compare MVSTW & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVSTW | RLAY |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | 1921 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MVSTW | RLAY |
|---|---|---|
| Price | $0.04 | $9.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 94.7K | ★ 2.0M |
| Earning Date | 03-14-2025 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $370,989,000.00 | $15,355,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $178.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 39.03 | ★ 53.44 |
| 52 Week Low | $0.03 | $1.78 |
| 52 Week High | $0.65 | $11.43 |
Technical Indicators
Market Signals| Indicator | MVSTW | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 34.21 | 59.25 |
| Support Level | $0.03 | $7.22 |
| Resistance Level | $0.07 | $11.43 |
| Average True Range (ATR) | 0.01 | 0.68 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 25.77 | 43.23 |
Price Performance
Historical ComparisonAbout MVSTW Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).